Abstract
Objective: In this study, we evaluated the effectiveness of amlodipine in patients with severe ischaemic left ventricular dysfunction (LVD) and mild to moderate heart failure, but not current angina, assessing the effects of the drug on symptoms, left ventricular function and exercise capacity.
Patients and Methods: We studied 36 patients with ischaemic LVD (radionuclide ejection fraction <40%, left ventricular end-diastolic dimension >60mm) and mild to moderate heart failure (NYHA class II or III) without angina treated with ACE inhibitors (36 of 36), digitalis (34 of 36) and diuretics (30 of 36). Among the 36 recruited patients, 33 fulfilled the study protocol, including 2 weeks of run-in (standard therapy), 8 weeks of treatment (standard therapy + amlodipine 5mg once daily) and 2 weeks of washout (standard therapy). Symptoms graded on a 10-point scale (heart failure score; a higher score representing improvement in symptoms), radionuclide left ventricular ejection fraction (rLVEF), echocardiographic left ventricular end-diastolic dimension (LVEDD), peak aerobic capacity (VO2max), exercise time (ET) and total work load (TWL) were measured after run-in, treatment and washout periods. All patients underwent coronary angiography and 201Thallium (T1) myocardial scintigraphy.
Results: With respect to baseline and washout, after amlodipine treatment the HF score improved (6.6 ±1.3 after amlodipine vs 5.9 ±1 at baseline and 5.9 ±1.1 at washout; p < 0.02), rLVEF increased (33.12 ±9.02% vs 29.14 ±7.72% and 30.02 ±7.39%, respectively; p < 0.001), and VO2max (14.35 ±4.05 ml/kg/min vs 12.68 ±3.21 ml/kg/min and 12.62 ±3.59 ml/kg/min, respectively; p < 0.003), ET (440 ±169 sec vs 395 ±158 sec and 402 ±162 sec, respectively; p < 0.02) and TWL (2183.2 ±439 kpm vs 1615.5 ±427 kpm and 1708.8 ±437 kpm, respectively; p < 0.01) were also increased. The increase in VO2max was related to systolic blood pressure at rest and at the peak of exercise, and to the presence of viable and/or ischaemic myocardium at 201Tl myocardial scintigraphy.
Conclusion: Amlodipine, in addition to standard therapy (including in all cases an ACE inhibitor), reduced symptoms and improved exercise capacity and ventricular function in patients with mild to moderate heart failure due to myocardial ischaemia. Thus, amlodipine is useful in patients with ischaemic LVD and heart failure without angina. The improvement in exercise capacity was greater in patients with scintigraphic evidence of viable and/or ischaemic myocardium and higher blood pressure. However, our study presented some limitations (i.e. an open study with few patients), and only generated a hypothesis that could lead to a wider, multicentre, cooperative trial.
Similar content being viewed by others
References
Pouleur H. Calcium antagonists or beta-blockers in chronic ischaemic left ventricular dysfunction? Eur Heart J 1993; 14: 26–8
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine —isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10
SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302
Pfeffer MA, Braunwald E, Moyè LA, et al., on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–77
Feldman AM. Can we alter survival in patients with congestive heart failure? JAMA 1992; 267: 1956–61
Elkayam U, Shotan A, Mehera A, et al. Calcium channel blockers in heart failure. Am J Cardiol 1993; 22: 139A–144A
Parameshwar J, Poole-Wilson PA. The role of calcium antagonists in treatment of chronic heart failure. Eur Heart J 1993; 14Suppl. F: 26–8
Packer M, Nicod P, Kandheria R, et al. Randomized, multicenter, double-blind, placebo controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991; 17: 274A
Smith WB, DeAbate AC, Gollub SB, et al. Beneficial long-term hemodynamic and clinical effect of amlodipine in chronic heart failure: results of a multicentric randomized, double blind, placebo controlled, dose-ranging study. Circulation 1994; 90:Suppl. I: 603A
Packer M, O’Connor CM, Ghali JK, et al., for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14
Pearlman AS, Gardin JM, Martin RP, et al. Guidelines for optimal physician training in echocardiography. Recommendations of the American Society of Echocardiography. Committee for Physician Training in Echocardiography. Am J Cardiol 1987; 60: 158–63
Wasserman K, Hansen JE, Sue DY, et al. Principles of exercise testing and interpretation. 2nd ed. Pennsylvania: Lea & Febiger, 1994
Franciosa JA, Dunkman WB, Leddy CL. Hemodynamic effects of vasodilators and long-term response in heart failure. Am J Cardiol 1984; 3: 1521–30
Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87Suppl. VI: 5–16
Bolli R. Myocardial stunning in man. Circulation 1992; 86: 1671–91
Vanoverschelde JLJ, Wijns W, Depré C, et al. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993; 87: 1513–23
Rahimtoola SH. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol 1995; 75: 16E–22E
Ferrari R. Calcium antagonists and left ventricular dysfunction. Am J Cardiol 1995; 75: 71E–76E
Gross GJ, Pieper GM. Beneficial actions of amlodipine in the multiple-stunned canine myocardium. Cardiovasc Drugs Ther 1992; 6: 67–75
Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels. An unexpected mechanism of action of a calcium channel blocking agent. Circulation 1998; 97: 576–80
Mohler ER, Sorensen LC, Ghali JK, et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. J Am Coll Cardiol 1997; 30: 35–41
Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994; 73: 28A–33A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perna, G.P., Valle, G., Cianfrone, N. et al. Amlodipine in Ischaemic Left Ventricular Dysfunction with Mild to Moderate Heart Failure. Clin. Drug Investig. 16, 289–296 (1998). https://doi.org/10.2165/00044011-199816040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199816040-00003